PCPaula Andrea Cárdenas‐Marín

Paula Andrea Cárdenas‐Marín

*This is an algorithmically generated author record based on publicly available information.

Paula Andrea Cárdenas‐Marín has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Outcomes of Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Cohort Study From a Latin American Care Center

    by Miller Giraldo‐Sandoval, Fernando Andrés Guerrero‐Pinedo, Ángela María Herrera‐Peña, Juan David Agrado‐Torres, Julián Mauricio Cortés‐Colorado, Frank Cañón‐Estrada, Carlos Andrés Mejía‐Gómez, María Alejandra Londoño‐Osorio, Juan Andrés Muñoz‐Ordoñez, Valeria Azcarate‐Rodríguez, et al.

    Chronic thromboembolic pulmonary hypertension (CTEPH) is a distinct subtype of pulmonary hypertension arising from persistent major pulmonary artery obstruction after pulmonary embolism. Pulmonary endarterectomy (PEA) remains the standard of care, but up to 40% of patients in European and US registries are inoperable; balloon pulmonary angioplasty (BPA) has emerged as a more accessible interventional modality for suitable patients. This retrospective single‐center cohort study evaluated functional improvement, hemodynamic response, and mortality in patients with CTEPH ineligible for PEA who underwent BPA at a Colombian institution (May 2022–October 2025). Risk was stratified using COMPERA 2.0. The primary outcome was improvement of at least one New York Heart Association (NYHA) functional class; secondary outcomes were change in mean pulmonary arterial pressure (mPAP) and all‐cause mortality during follow‐up. Of 33 patients (median age 63 years; 70% female), 5 (15.1%) were high risk at baseline, 16 (48.4%) intermediate‐high, 10 (30.3%) intermediate‐low, and 2 (6%) low risk. After BPA, 19 patients (58%) improved NYHA class (95% CI, 39.2%–74.5%), and mPAP fell from 60 (IQR 50–68) to 40 mmHg (IQR 37–48) after a median of three sessions (IQR 2–4) (mean paired reduction 14.05 mmHg, 95% credible interval 9.81–18.07; Hedges’ g = 1.22, 95% CI 0.77–1.66). Two deaths (6.0%) occurred, both in high‐risk patients. BPA improved NYHA class and pulmonary hemodynamics in severe, inoperable CTEPH, with a low complication rate despite advanced baseline disease. COMPERA 2.0 stratified baseline severity but did not predict the magnitude of hemodynamic response to BPA, consistent with the mechanical nature of the disease.

  • Open Access

    Percutaneous Closure of an Ischemic Ventricular Septal Rupture in a 73-Year-Old Man: A Case Report

    by Carlos Andres Mejia-Gomez, Paula Andrea Cardenas Marin, Maria Juliana Reyes-Cardona, Miller Giraldo-Sandoval, Camilo Andres Calderon-Miranda, Jorge Alexander Zambrano-Franco, Pastor Olaya, Jairo Sanchez-Blanco, Carlos Enrique Vesga-Reyes

    BACKGROUND Acquired ventricular septal defect is an uncommon complication of myocardial infarction that can require surgical repair. Percutaneous closure techniques avoid the risks associated with major cardiac surgery, particularly in elderly patients. This report presents the case of a 73-year-old man with a post-infarction ventricular septal defect successfully treated by percutaneous closure. CASE REPORT A 73-year-old man was admitted with ST-elevation myocardial infarction. Coronary angiography revealed 2-vessel disease, and successful stenting of the left anterior descending artery was performed. Transthoracic echocardiography demonstrated an apical ventricular septal defect. Given the patient's hemodynamic stability, the heart team recommended delayed percutaneous closure. However, the patient requested voluntary discharge. He was readmitted 2 weeks later with dyspnea and chest pain. The defect was closed percutaneously due to technical feasibility, elevated surgical risk, and patient preference. Post-procedural recovery was uneventful, and he was in NYHA functional class I at outpatient follow-up. CONCLUSIONS Ischemic ventricular septal rupture is a rare but potentially fatal complication of transmural myocardial infarction, requiring prompt recognition and management by a heart team. Presentation ranges from chest pain or a new murmur to cardiogenic shock. Diagnosis relies on imaging modalities, including transthoracic or transesophageal echocardiography and cardiac magnetic resonance imaging. Management options include surgical and percutaneous closure, with ventricular septal rupture repair mortality exceeding 40%. Treatment selection depends on the patient's clinical status and the size, location, and complexity of the defect. This report highlights the role of percutaneous closure in post-infarction ventricular septal rupture and illustrates a successful outcome in an elderly patient.

  • Open Access

    Postpartum ischemic stroke due to persistent left superior vena cava to left atrium after DORV repair: a case report and literature review

    by Paula Andrea Cárdenas-Marín, Jorge Alexander Zambrano-Franco, Maria Juliana Reyes-Cardona, Camilo Andres Calderon-Miranda, Jairo Sanchez-Blanco, Pastor Olaya, Carlos Enrique Vesga-Reyes

    Background: Persistent left superior vena cava (PLSVC) is the most common thoracic venous anomaly and is often associated with complex congenital heart disease (CHD). Venous drainage typically occurs into the right atrium via the coronary sinus (CS). However, in 10–20% of cases, it drains into the left atrium, producing a right-to-left shunt that may result in symptoms and cerebrovascular complications. Case presentation: A 23-year-old woman with a history of double-outlet right ventricle corrected at age 13 presented in the postpartum period with dysarthria, left central facial palsy and left hemiparesis. Brain MRI angiography revealed right middle cerebral artery (M2) occlusion, and she underwent thrombolysis and thrombectomy. Suspecting a cardioembolic event, transesophageal echocardiography with left-arm agitated saline injection revealed early left atrial opacification and delayed right-sided filling via a residual ventricular septal defect —suggesting a PLSVC draining into the left atrium. Cardiac CT confirmed CS agenesis and a PLSVC connected to the left atrial roof. She was discharged on enoxaparin. Conclusions: PLSVC is a vascular anomaly with an estimated prevalence of 0.2-3% in the general population and 1-12% among CHD patients. A dilated CS on transthoracic echocardiography should prompt a bubble test; early opacification of the left chambers after left-arm saline injection suggests drainage to the left atrium. Cardiac CT, MRI or invasive angiography can clarify the anatomy. PLSVC has clinical implications including technical considerations for percutaneous procedures and cardiac surgery, a predisposition for arrhythmias, and —when draining into the left atrium— an increased risk of cerebrovascular events. Closure of a PLSVC draining into the left atrium should be considered in symptomatic patients or those at high risk of paradoxical embolism, following anatomical assessment. In pregnant women with CHD, cardiac risk assessment, multimodal imaging and multidisciplinary follow-up are crucial due to associated hemodynamic changes and hypercoagulable state.


  • Open Access

    American Registry of Ambulatory or acutely decompensated heart failure (AMERICCAASS Registry): First 1000 patients

    by Juan Esteban Gómez‐Mesa, Juliana María Gutiérrez‐Posso, Manuela Escalante‐Forero, Brayan Daniel Córdoba‐Melo, Paula Andrea Cárdenas‐Marín, Eduardo R. Perna, Mádelyn Raquel Valle‐Ramos, Germán Camilo Giraldo‐González, Noel Alberto Flórez‐Alarcón, Ida Fabiola Rodríguez‐Caballero, et al.

    Background: About 80% of cardiovascular diseases (including heart failure [HF]) occur in low‐income and developing countries. However, most clinical trials are conducted in developed countries.Hypothesis: The American Registry of Ambulatory or Acutely Decompensated Heart Failure (AMERICCAASS) aims to describe the sociodemographic characteristics of HF, comorbidities, clinical presentation, and pharmacological management of patients with ambulatory or acutely decompensated HF in America.Methodology: Descriptive, observational, prospective, and multicenter registry, which includes patients >18 years with HF in an outpatient or hospital setting. Collected information is stored in the REDCap electronic platform. Quantitative variables are defined according to the normality of the variable using the Shapiro–Wilk test.Results: This analysis includes data from the first 1000 patients recruited. 63.5% were men, the median age of 66 years (interquartile range 56.7–75.4), and 77.6% of the patients were older than 55 years old. The percentage of use of the four pharmacological pillars at the time of recruitment was 70.7% for beta‐blockers (BB), 77.4% for angiotensin‐converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB II)/angiotensin receptor‐neprilysin inhibitor (ARNI), 56.8% for mineralocorticoid receptor antagonists (MRA), and 30.7% for sodium–glucose cotransporter type‐2 inhibitors (SGLT2i). The main cause of decompensation in hospitalized patients was HF progression (64.4%), and the predominant hemodynamic profile was wet‐warm (68.3%).Conclusions: AMERICCAASS is the first continental registry to include hospitalized or outpatient patients with HF. Regarding optimal medical therapy, approximately a quarter of the patients still need to receive BB and ACEI/ARB/ARNI, less than half do not receive MRA, and more than two‐thirds do not receive SGLT2i.